Skip to main content

CON-TGO91-280 - Sanofi Aventis Australia Pty Ltd

Product names
  • AUST R 221717 - CLEXANE enoxaparin sodium 20mg/0.2mL injection syringe with automatic safety lock system
  • AUST R 221718 - CLEXANE enoxaparin sodium 40mg/0.4mL injection syringe with automatic safety lock system
  • AUST R 221719 - CLEXANE enoxaparin sodium 60mg/0.6mL injection syringe with automatic safety lock system
  • AUST R 221720 - CLEXANE enoxaparin sodium 80mg/0.8mL injection syringe with automatic safety lock system
  • AUST R 221721 - CLEXANE enoxaparin sodium 100mg/1mL injection syringe with automatic safety lock system
  • AUST R 221722 - CLEXANE FORTE enoxaparin sodium 120mg/0.8mL injection syringe with automatic safety lock system
  • AUST R 221723 - CLEXANE FORTE enoxaparin sodium 150mg/1mL injection syringe with automatic safety lock system
Decision Date
Duration
The consent is effective for all batches manufactured between 1 September 2020 and 31 March 2021.
Non-compliance with standard

The product(s) do not conform with the requirements of TGO 91 but are supplied with label(s) that have been approved by the TGA.

Supply/Import or Export
Supply
Therapeutic good type
Prescription medicines

Help us improve the Therapeutic Goods Administration site